AdaptHealth Corp vs Anheuser-Busch Inbev SA — how do they compare? AdaptHealth Corp trades at $5.8 (market cap $753.09M), while Anheuser-Busch Inbev SA trades at $79.34 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 211.1× AdaptHealth Corp's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | BUD | |
|---|---|---|
Market Cap | $753.09M | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $13.38 | $86.48 |
52-Week Low | $5.22 | $57.93 |
Enterprise Value | $2.77B | $223.42B |
Dividend Yield | — | 1.67% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.63, up 7.85% today but remains under significant pressure after recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal negative profitability with a -6.82% net margin and three consecutive quarterly earnings misses. The company is restructuring by selling its diabetes unit to focus on sleep and respiratory care, but faces multiple securities fraud investigations following guidance revisions.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting 95% upside, substantial risks exist including ongoing legal probes, execution challenges with new fixed-price contracts, and negative cash flow trends. The stock presents high-risk speculation amid operational restructuring and legal uncertainties.
BUD trades at $83.09, down 0.8% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains solid profitability with a 14.9% net income margin and positive cash flow trends. News highlights institutional activity and earnings discussions, with a consensus price target of $90.17 suggesting upside potential.
The outlook for BUD is positive, driven by earnings growth projections and a favorable valuation with a P/E of 17.37. Risks include competitive pressures and macroeconomic volatility, but institutional support and bullish analyst ratings indicate confidence in continued performance. The stock presents a growth opportunity with manageable risks for investors seeking exposure to the consumer staples sector.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →